Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Halabi, S.
Rini, B. I.
Stadler, W. M.
Small, E. J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [32] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, C. D.
    Clark, K. L.
    Ashing, K. T.
    Almeida, L.
    Bergerot, P. G.
    Obenchain, R.
    Dizman, N.
    Hsu, J.
    Maia, M. C.
    Philip, E.
    Loscalzo, M.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS' SEQUENTIALLY TREATED WITH TARGETED THERAPIES (TTS)
    Procopio, G.
    Verzoni, E.
    Testa, I.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [35] APPLICATION OF MACHINE LEARNING (ML) TO PREDICT PROGRESSION-FREE SURVIVAL (PFS) IN ADVANCED RENAL CELL CARCINOMA (RCC).
    Shahin, M.
    Li, J.
    Lin, S.
    Nickens, D.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S74 - S75
  • [36] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [37] Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA.
    Escudier, B. J.
    Negrier, S.
    Perol, D.
    Gravis, G.
    Delva, R.
    Bay, J.
    Geoffrois, L.
    Legouffe, E.
    Metzger, S.
    Ferlay, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Kucharz, Jakub
    Dumnicka, Paulina
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL ONCOLOGY, 2019, 36 (02)
  • [39] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Jakub Kucharz
    Paulina Dumnicka
    Beata Kusnierz-Cabala
    Tomasz Demkow
    Pawel Wiechno
    Medical Oncology, 2019, 36
12345